EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms

Sophie M Ansems iD, Marjolein Y Berger iD, Patrick F van Rheenen iD, Karin M Vermeulen iD, Michiel R de Boer iD, Gea A Holtman iD

British Journal of General Practice · 2025

DOI: 10.3399/bjgp.2025.0334 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of General Practice, 2025. Verfasst von Sophie M Ansems und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Referral and Consultation, Feces, Abdominal Pain. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triage of children with chronic abdominal symptoms who benefit from pediatric specialist care is challenging for general practitioners (GPs).

Aim

To evaluate (cost-)effectiveness of fecal calprotectin (FCal)-testing to guide referral to specialist care in children with chronic abdominal symptoms.

Methods

Pragmatic, cluster-randomized controlled trial with 1:1 randomization of Dutch GP practices between October 2019 and July 2021. GPs in the intervention group followed an FCal-guided referral strategy and the control group Dutch GP guidelines, which do not recommend FCal-testing. Eighty-four GP practices included 405 children aged 4-18 years with chronic abdominal pain and/or diarrhoea. Primary outcome was specialist referral within 6 months after baseline consultation. Incremental cost-effectiveness ratios (ICERs) were calculated from the societal perspective based on parental concern. Intention-to-treat (ITT) analyses and per-protocol (PP) analyses (strategy adherence in intervention group and no FCal use in control group) were conducted.

Results

Adherence to FCal-strategy was 59%. Alarm symptoms for IBD were more prevalent in the intervention (26.6%) than the control group (8.9%) with similar referral rates in the ITT analysis (22.8 vs 21.9%; adjusted odds ratio (aOR) 0.94, 95%CI 0.57-1.54) and fewer referrals for the intervention group in the PP analysis (5.8% vs 20.3%; aOR 0.21, 95%CI 0.09-0.50). The intervention was not cost-effective in the ITT analysis (ICER €1534; 95%CI -€9019-€9579), but cost-effective in the PP analysis (ICER -€344; 95 %CI -€4609-€3096).

Conclusion

The results do not justify recommending FCal testing in children in primary care without proper implementation. Additional research should focus on improving adherence to the FCal-strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexReferral and ConsultationFecesAbdominal PainDiarrheaInflammatory Bowel DiseasesHumansCost-Benefit AnalysisChildMaleFemaleAdolescentChild, PreschoolNetherlandsChronic Disease

Stichwörter der Autor:innen

childfaecal calprotectinfunctional gastrointestinal diseaseinflammatory bowel diseasesprimary health care

Substanzen

Leukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Paediatric Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands g.a.holtman@umcg.nl.

ORCID-Profile: Sophie M Ansems, Marjolein Y Berger, Patrick F van Rheenen, Karin M Vermeulen, Michiel R de Boer, Gea A Holtman

Zitieren

APA

Ansems, S. M., Berger, M. Y., van Rheenen, P. F., Vermeulen, K. M., de Boer, M. R., & Holtman, G. A. (2025). Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms. British Journal of General Practice. https://doi.org/10.3399/bjgp.2025.0334

Vancouver

Ansems SM, Berger MY, van Rheenen PF, Vermeulen KM, de Boer MR, Holtman GA. Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms. British Journal of General Practice. 2025. doi:10.3399/bjgp.2025.0334

BibTeX
@article{Ansems2025,
  author = {Ansems, Sophie M and Berger, Marjolein Y and van Rheenen, Patrick F and Vermeulen, Karin M and de Boer, Michiel R and Holtman, Gea A},
  title = {Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms},
  journal = {British Journal of General Practice},
  year = {2025},
  doi = {10.3399/bjgp.2025.0334}
}
Kostenlos starten →